{"id":13308,"date":"2020-07-01T11:27:39","date_gmt":"2020-07-01T09:27:39","guid":{"rendered":"https:\/\/idibell.cat\/?p=13308"},"modified":"2021-07-28T14:56:51","modified_gmt":"2021-07-28T12:56:51","slug":"la-combinacio-de-quatre-farmacs-a-baixes-dosis-evita-laparicio-de-resistencies-i-es-menys-toxica-en-el-tractament-dun-tipus-de-cancer-de-pulmo","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2020\/07\/la-combinacio-de-quatre-farmacs-a-baixes-dosis-evita-laparicio-de-resistencies-i-es-menys-toxica-en-el-tractament-dun-tipus-de-cancer-de-pulmo\/","title":{"rendered":"La combinaci\u00f3 de quatre f\u00e0rmacs a baixes dosis evita l\u2019aparici\u00f3 de resist\u00e8ncies i \u00e9s menys t\u00f2xica en el tractament d\u2019un tipus de c\u00e0ncer de pulm\u00f3"},"content":{"rendered":"<p>El tractament habitual de molts c\u00e0ncers consisteix en bloquejar l&#8217;activitat espec\u00edfica de la prote\u00efna afectada per una mutaci\u00f3 concreta utilitzant altes dosis d\u2019un f\u00e0rmac. Aquesta estrat\u00e8gia, tot i ser efectiva d\u2019inici, comporta que les c\u00e8l\u00b7lules tumorals acabin desenvolupant <strong>resist\u00e8ncies al tractament<\/strong> mitjan\u00e7ant l\u2019aparici\u00f3 de mutacions secund\u00e0ries, que potencien vies alternatives de creixement, i permeten a les c\u00e8l\u00b7lules esquivar l&#8217;efecte del f\u00e0rmac. Aquest \u00e9s el cas del c\u00e0ncer de pulm\u00f3 de c\u00e8l\u00b7lula no petita (<strong>NSCLC<\/strong>), causat per mutacions al receptor EGFR, en el qual el tractament amb inhibidors d&#8217;EGFR desencadena l\u2019aparici\u00f3 de resist\u00e8ncia adquirida a la ter\u00e0pia dirigida.<\/p>\n<p>L\u2019estudi dirigit pel Dr. Ren\u00e9 Bernards del Netherlands Cancer Institute (<a href=\"https:\/\/www.nki.nl\/\">NKI<\/a>), amb la col\u00b7laboraci\u00f3 dels investigadors Alberto Villanueva i Ernest Nadal de l&#8217;Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (<a href=\"https:\/\/idibell.cat\/\">IDIBELL<\/a>) i de l&#8217;Institut Catal\u00e0 d&#8217;Oncologia (<a href=\"http:\/\/ico.gencat.cat\/ca\/inici\">ICO<\/a>), i Agust\u00ed Vidal del Hospital Universitari de Bellvitge, ha desenvolupat una nova aproximaci\u00f3 terap\u00e8utica per tractar aquest tipus de tumors a trav\u00e9s d\u2019un c\u00f2ctel de f\u00e0rmacs a dosis baixes, anomenat <strong>MLD<\/strong> (del angl\u00e8s, Multilpe Low Dose). Aquesta combinaci\u00f3 t\u00e9 com objectiu inhibir de forma simult\u00e0nia l\u2019acci\u00f3 de diverses prote\u00efnes d\u2019una mateixa via de senyalitzaci\u00f3 imprescindible per la c\u00e8l\u00b7lula tumoral.<\/p>\n<p>Concretament, en aquest estudi publicat a la revista <a href=\"https:\/\/www.nature.com\/articles\/s41467-020-16952-9\"><em>Nature Communications<\/em><\/a>, mostren que com a m\u00ednim un 20% de la dosi efectiva dels f\u00e0rmacs \u00e9s suficients per bloquejar completament la via de senyalitzaci\u00f3 i la proliferaci\u00f3 de les c\u00e8l\u00b7lules, quan s\u2019utilitza la combinaci\u00f3 de quatre inhibidors. En els estudis <em>in vitro<\/em> en l\u00ednies cel\u00b7lulars, aix\u00ed com en models animals generats mitjan\u00e7ant la implantaci\u00f3 de bi\u00f2psies de pacients en els pulmons de ratolins, es van veure respostes duradores a la ter\u00e0pia MLD sense toxicitat associada. Tot i que, cada f\u00e0rmac per separat en dosis baixes no tenia cap efecte, la combinaci\u00f3 dels quatre implicava un efecte sin\u00e8rgic que aconseguia aturar el creixement tumoral.<\/p>\n<p>Els resultats d&#8217;aquest estudi mostren que utilitzar la combinaci\u00f3 de diversos f\u00e0rmacs que actu\u00efn sobre diferents components d&#8217;una via de comunicaci\u00f3 necess\u00e0ria per a les c\u00e8l\u00b7lules tumorals, i a m\u00e9s, fer-ho en dosis baixes, comporta una efic\u00e0cia a m\u00e9s llarg termini dels tractaments antitumorals, i evita l&#8217;aparici\u00f3 de resist\u00e8ncies per parts de les c\u00e8l\u00b7lules tumorals. Tot i que de moment nom\u00e9s s&#8217;ha provat en un tipus de tumors de pulm\u00f3, els investigadors creuen que aquesta nova aproximaci\u00f3\u00a0 podria ser extensible altres tipus de tumors. Es planteja iniciar <strong>assaigs cl\u00ednics<\/strong> per comprovar l&#8217;efic\u00e0cia d&#8217;aquesta estrat\u00e8gia en pacients amb tumors NSCLC portadors de la mutaci\u00f3 d\u2019EGFR.<\/p>\n<p>Aquest estudi ha comptat tamb\u00e9 amb la col\u00b7laboraci\u00f3 de la Dra. Enriqueta Felip i el Dr. Alex Mart\u00edn de la Vall d&#8217;Hebron-VHIO.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>L\u2019estudi, publicat a la revista Nature Communications, liderat pel Netherlands Cancer Institute (NKI), ha comptat amb la col\u00b7laboraci\u00f3 d\u2019investigadors de l\u2019IDIBELL\/ICO i del HUB. En ell es demostrat l&#8217;efecte benefici\u00f3s de l\u2019\u00fas d\u2019un c\u00f2ctel de f\u00e0rmacs a dosis baixes, per bloquejar una mateixa ruta de senyalitzaci\u00f3 cel\u00b7lular, en un tipus de c\u00e0ncer de pulm\u00f3.<\/p>\n","protected":false},"author":8,"featured_media":13309,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,447,452,346,333],"tags":[],"class_list":["post-13308","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell","category-procure","category-quimioresistencia-tumoral-i-estromal","category-metabolisme-i-mort-cellular"],"publishpress_future_action":{"enabled":false,"date":"2024-11-25 03:22:15","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/13308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=13308"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/13308\/revisions"}],"predecessor-version":[{"id":18600,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/13308\/revisions\/18600"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/13309"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=13308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=13308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=13308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}